Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | TFPI2 | P48307 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.37 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301135 | 1.00 | POLB (0.52) | POLBKDM4EL3MBTL1TDP1TFPI2 | |
| SCHEMBL25467330 | 1.00 | POLB (0.52) | POLBKDM4EL3MBTL1TDP1TFPI2 | |
| SCHEMBL18419252 | 1.00 | POLB (0.52) | POLBKDM4EL3MBTL1TDP1TFPI2 | |
| SCHEMBL301620 | 0.97 | POLB (0.50) | POLBKDM4EL3MBTL1TDP1TFPI2 | |
| SCHEMBL9132022 | 0.97 | POLB (0.50) | POLBKDM4EL3MBTL1TDP1TFPI2 | |
| SCHEMBL5806994 | 0.97 | POLB (0.50) | POLBKDM4EL3MBTL1TDP1TFPI2 | |
| SCHEMBL30978583 | 0.94 | — | — | |
| SCHEMBL3983189 | 0.94 | — | — | |
| SCHEMBL15369748 | 0.94 | — | — | |
| SCHEMBL26077289 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2020257135-A1 | TRIAZOLE CARBOXYLIC ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-1562575-B1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | ABBOTT LAB (US) | 2009-05-20 | — | — | EP | disclosed |
| US-20040209859-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-10-21 | — | — | US | disclosed |
| US-20040077617-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209859-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | GRIN2A, GRIK1, GRIN2B | POLB 2882/4885KDM4E 3569/4885L3MBTL1 3988/4885 |
| US-20260115199-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CCR6 | POLB 1755/4885KDM4E 2405/4885L3MBTL1 385/4885 |
| US-20040077617-A1 | Fused cycloalkyl amides and acids and their therapeutic applications | GRIN2A, GRIK1, GRIN2B | POLB 2882/4885KDM4E 3569/4885L3MBTL1 3988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.